Group items tagged

Artificial intelligence (AI) in healthcare is the use of algorithms and software. its applications in healthcare and even its definition.

Artificial Intelligence, AI, AI in HealthCare, Artificial Intelligence In Healthcare, Insights Care, Best HealthCare Magazine

Healthcare has a strong relationship with technology. The modern structure of hospitals and medical facilities cannot function without the progress of technology. It is important to acknowledge the impact of technology to ensure that priority is given to the constant maintenance of innovation. Here are a few ways to understand how healthcare and technology operate together. TECHNOLOGICAL INNOVATIONS KEEPING UP WITH MEDICAL DEMANDS Healthcare has become increasingly dependent upon technology throughout the years. There is an almost infinite amount of equipment and machinery that is used on a day-to-day basis to help facilitate the care of patients. One aspect that needs to be acknowledged is the prevalence of smart technology within the hospital and healthcare spaces. Technology is being innovated, and it is only a matter of time until hospitals see such advancements be applied more often, as funding increases alongside the development of new machinery and equipment. These include the inclusion of artificial intelligence in order to assist and supplement healthcare professionals to do a better and more efficient job, providing better care for patients. Of course, such technology will need to follow trends of other industries first to ensure its safe use and application when dealing with patients.

The World Health Organization called for caution on Tuesday (May 16) in using artificial intelligence for public healthcare, saying data used by AI to reach decisions could be biased or misused. The WHO said it was enthusiastic about the potential of AI but had concerns over how it will be used to improve access to health information, as a decision-support tool and to improve diagnostic care. The WHO said in a statement the data used to train AI may be biased and generate misleading or inaccurate information and the models can be misused to generate disinformation. It was "imperative" to assess the risks of using generated large language model tools (LLMs), like ChatGPT, to protect and promote human wellbeing and protect public health, the U.N. health body said.

At the Future of Britain Conference 2024, the newly appointed Secretary of Health and Social Care, (DHSC) Wes Streeting, stated that "Labour's DNA is in the NHS". He also called for a long-term approach to reform the broken health sector and the integration of artificial intelligence (AI) to steer the healthcare system towards sustainability and growth. Hosted by Tony Blair Institute for Global Change and My Life My Say today, Tuesday, 9, Streeting discussed the plans to fix the healthcare system and role of Artificial Intelligence (AI) in "making the right choices" by bringing in three essential shifts in the healthcare. Criticising the previous Conservative administration for leaving "massive burning deck issues" due to constant reshuffling within the Department of Health and Social Care (DHSC), Streeting lamented that this "instability" and "indecisions" have made comprehensive reform even more pressing. Drawing inspiration from Chancellor Rachel Reeves' speech on economic growth, Streeting stressed the interconnectedness of health and economic prosperity.

Over the last few years pharmacy and the role of pharmacy teams has changed dramatically. The introduction of technology and the integration of artificial intelligence (AI) within systems that provide healthcare and support to pharmacies holds great promise; for improving access to health, supporting patient outcomes, and optimising operational efficiency. Currently, the potential use of AI could span the whole of the medicines value chain, from AI-driven drug discovery to personalised medicines and automated dispensing systems. However, the rapid advancement of AI technology does raise several ethical concerns. This article will explore these concerns and how they can be addressed. In previous articles, I have discussed what underpins artificially intelligent machines and the importance of data. Datasets are the foundation on which AI algorithms learn and generate conclusions. The first step to understanding the potential ethical implications of AI across the pharmacy sector is to understand the data that is held within these foundational datasets. Patient privacy and data security AI systems in and outside of the pharmacy sector, which support patient care, rely heavily on vast amounts of medical data (patient medical records, PMR data, etc). However, the collection, storage, and use of such sensitive data can possibly bring significant privacy concerns. GDPR compliance is essential within the UK and ethical questions arise around data ownership, patient consent, and the possibility of data and cybersecurity breaches. As frontline healthcare professionals, we need to be able to support our patients when questions are asked about their data. For example, how can patients be sure their data is used only for its intended purposes? Is anonymised data truly safe from de-identification techniques that could expose private information?

The Company Chemists' Association (CCA) has voiced strong support for a recent report from the Tony Blair Institute (TBI), which advocates for the establishment of a 'Digital Health Record' (DHR) for every individual in the UK. The CCA, which was interviewed as part of the report's development, believes that the creation of a DHR could significantly enhance the NHS's efficiency, improve preventative healthcare, and help the health service harness the full potential of artificial intelligence (AI). The TBI report highlights that the current health and care system suffers from fragmented data, with individual records scattered across various providers, including community pharmacies. This siloed approach often hampers the delivery of seamless and effective care. A unified DHR, the report argues, would consolidate all relevant health data into a single, accessible record, ensuring that patients receive timely and appropriate care across the entire healthcare system.

In a recent announcement the Medicines and Healthcare products Regulatory Agency (MHRA) unveiled its strategic approach to artificial intelligence (AI), as it sets out to embrace the transformative potential of AI in healthcare regulation. Building upon the Government's white paper 'A pro-innovation approach to AI regulation', released in 2023, the MHRA outlined five key strategic principles guiding its adoption of AI. These principles encompass safety, security, and robustness; appropriate transparency and explainability; fairness, accountability, and governance; and contestability and redress. A science-led organization, the MHRA was tasked with providing an independent view of its approach to AI in medicine and science, aligning with a government white paper. Recognising its role in UK's goal to be a science and tech leader by 2030, MHRA is tasked to evaluate AI's opportunities and risks across regulatory, public service, and evidence-based decision-making area.

The healthcare landscape has dramatically changed over the years, due to a number of factors, firstly having to navigate Covid-19 and now the advancement of artificial intelligence (AI) and machine technology, to name a few. As a result, training the next generation of healthcare leaders is more important now than ever. Let's look at three ways to effectively train the next generation of pharmacists: Robust Induction Programme Induction programs are an effective way of training the next generation of pharmacists as they have the ability to provide knowledge, skills and practical experience to deal with and manage common challenges they're likely to experience in their careers. These programs usually include training in pharmacokinetics, drug dosages, medication administration, and pharmacotherapy.

The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK. Through this funding, the government aims to create the most advanced genomic healthcare system in the world. "Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a £175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC. The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA. "£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC. "An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information such as routine scans.

The Department of Health and Social Care (DHSC) made a recent announcement that the Incubator for Artificial Intelligence (i.AI) and NHS England (NHSE) have joined forces in a groundbreaking move by signing a Collaboration Charter on AI. This pivotal partnership aims to equip the NHS workforce with the tools and resources to leverage AI technology for enhancing patient care, improving staff experience, and driving operational efficiency. The Charter, endorsed by Minister Burghart, Parliamentary Secretary for the Cabinet Office, and Lord Markham, Parliamentary Under Secretary of State at the DHSC, signifies an important step towards integrating AI into the fabric of the NHS. Under this collaboration, the i.AI team, comprising elite technical experts within the government, will identify opportunities where AI technology can be deployed responsibly to support the NHS. This initiative is expected to streamline processes, optimize resource allocation, and ultimately enhance patient outcomes.

The Royal Pharmaceutical Society (RPS) has published a new policy outlining how artificial intelligence (AI) can be used to support pharmacy practice and improve patient care. The content has been developed in consultation with RPS members, Expert Advisory Group members, Board members, multi-professional experts in digital technology and AI, and external stakeholders including the General Pharmaceutical Council (GPhC). The policy highlights the opportunities, challenges and potential applications of AI within pharmacy now and in the future. RPS President, Professor Claire Anderson, acknowledges that AI technologies have the potential to transform pharmacy practice, noting that "there are some great examples where it's already in use." "We must optimise the opportunities that these advancing technologies can bring to enhance patient access to care, improve patient experience, support clinical decision making and improve the safety and efficiency of the medicines supply chain. "Our policy provides a framework to ensure AI is harnessed safely and effectively to support pharmacists and patients," she adds.

The UK government has pledged £133m to healthcare innovation funding, which will help boost the country's innovations in medical imaging and artificial intelligence (AI), among other areas.

Today, pharmaceutical companies can't simply make an effective drug and count on healthcare providers (HCPs) to come to them - they have to find innovative ways to attract them. Statista shows that in 2015 there were only 3,286 pharma companies with active research and development pipelines. In 2023, this number jumped to more than 5,500. As an earth-shattering number of new drugs are flooding the market each year, HCPs are having a hard time determining the best medicine for their patients. Meanwhile, pharma companies invest more in marketing to help HCPs get rid of choice paralysis and make them choose their solution over that of competitors. In this article, we will share the tried-and-true tactics to build a strong pharma brand. Get creative with interactive email marketing One…two…three…No, we're not counting to run a marathon. Three seconds is what you've got to pull your reader in with your email. Fail to quickly grab the audience's attention? We've got some bad news for you. Nobody's going to bother reading about how amazing your pharmaceutical product is if you're churning out generic emails with artificial intelligence tools.

The Medicines and Healthcare products Regulatory Agency (MHRA) is doubling down on its efforts to combat online pharmacy frauds, emphasising innovation, eradication of legacy systems, and cybersecurity in its updated technology roadmap. The online sale of medicines and medical devices is a "growing phenomenon offering convenience, anonymity, and lower prices " for the public. However the lack of robust cyber monitoring also "poses significant risks", as many online pharmacies are "unregulated, illegal, or fraudulent." According to the MHRA's recent report highlighting the impact of artificial intelligence on the regulation of medical products, the strategic themes of "fundamental to the successful deployment of AI" are essential for protecting consumers from fraudulent medical products.

Transitioning from analogue to digital is one of three major "shifts" the government has deemed essential for the future of the NHS. These shifts, with the other two being the moving from hospital to community care and from sickness to prevention, will also form the foundation of the 10-Year Health Plan. The question is: are the public ready to embrace this digital transformation, which would involve sharing their health data for the development of artificial intelligence (AI) systems within the NHS? Results from a UK-wide poll show that the majority of people (75 per cent) are willing to share some of their health data for AI development. The survey commissioned by the Health Foundation included more than 7,000 members of the public (aged 16 years and older). Nearly 60 per cent expressed willingness to share information about their eye health, with 58 per cent open to sharing details about the medications they are taking, and 57 per cent willing to disclose any long-term illnesses they live with.